These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

142 related articles for article (PubMed ID: 23396090)

  • 1. Overcoming chemotherapy resistance of ovarian cancer cells by liposomal cisplatin: molecular mechanisms unveiled by gene expression profiling.
    Koch M; Krieger ML; Stölting D; Brenner N; Beier M; Jaehde U; Wiese M; Royer HD; Bendas G
    Biochem Pharmacol; 2013 Apr; 85(8):1077-90. PubMed ID: 23396090
    [TBL] [Abstract][Full Text] [Related]  

  • 2. How liposomal Cisplatin overcomes chemoresistance in ovarian tumour cells.
    Stölting DP; Borrmann M; Koch M; Wiese M; Royer HD; Bendas G
    Anticancer Res; 2014 Jan; 34(1):525-30. PubMed ID: 24403511
    [TBL] [Abstract][Full Text] [Related]  

  • 3. IRF-1 expression is induced by cisplatin in ovarian cancer cells and limits drug effectiveness.
    Pavan S; Olivero M; Corà D; Di Renzo MF
    Eur J Cancer; 2013 Mar; 49(4):964-73. PubMed ID: 23079474
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Association between cisplatin resistance and mutation of p53 gene and reduced bax expression in ovarian carcinoma cell systems.
    Perego P; Giarola M; Righetti SC; Supino R; Caserini C; Delia D; Pierotti MA; Miyashita T; Reed JC; Zunino F
    Cancer Res; 1996 Feb; 56(3):556-62. PubMed ID: 8564971
    [TBL] [Abstract][Full Text] [Related]  

  • 5. p53 is a determinant of X-linked inhibitor of apoptosis protein/Akt-mediated chemoresistance in human ovarian cancer cells.
    Fraser M; Leung BM; Yan X; Dan HC; Cheng JQ; Tsang BK
    Cancer Res; 2003 Nov; 63(21):7081-8. PubMed ID: 14612499
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Akt-mediated cisplatin resistance in ovarian cancer: modulation of p53 action on caspase-dependent mitochondrial death pathway.
    Yang X; Fraser M; Moll UM; Basak A; Tsang BK
    Cancer Res; 2006 Mar; 66(6):3126-36. PubMed ID: 16540663
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Human melanoma cells selected for resistance to apoptosis by prolonged exposure to tumor necrosis factor-related apoptosis-inducing ligand are more vulnerable to necrotic cell death induced by cisplatin.
    Zhang XD; Wu JJ; Gillespie S; Borrow J; Hersey P
    Clin Cancer Res; 2006 Feb; 12(4):1355-64. PubMed ID: 16489094
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Overcoming cisplatin resistance of ovarian cancer cells by targeted liposomes in vitro.
    Krieger ML; Eckstein N; Schneider V; Koch M; Royer HD; Jaehde U; Bendas G
    Int J Pharm; 2010 Apr; 389(1-2):10-7. PubMed ID: 20060458
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Sensitization of cis-platinum by a recombinant adenovirus vector expressing wild-type p53 gene in human ovarian carcinomas.
    Song K; Li Z; Seth P; Cowan KH; Sinha BK
    Oncol Res; 1997; 9(11-12):603-9. PubMed ID: 9563008
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Synergistic effects of suberoylanilide hydroxamic acid combined with cisplatin causing cell cycle arrest independent apoptosis in platinum-resistant ovarian cancer cells.
    Ong PS; Wang XQ; Lin HS; Chan SY; Ho PC
    Int J Oncol; 2012 May; 40(5):1705-13. PubMed ID: 22328352
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Tubeimoside I sensitizes cisplatin in cisplatin-resistant human ovarian cancer cells (A2780/DDP) through down-regulation of ERK and up-regulation of p38 signaling pathways.
    Liu HZ; Yu C; Yang Z; He JL; Chen WJ; Yin J; Li WM; Liu HT; Wang YX
    Mol Med Rep; 2011; 4(5):985-92. PubMed ID: 21687949
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Biological comparison of ovarian cancer resistant cell lines to cisplatin and Taxol by two different administrations.
    Yan XD; Li M; Yuan Y; Mao N; Pan LY
    Oncol Rep; 2007 May; 17(5):1163-9. PubMed ID: 17390060
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Loss of caspase-8 activation pathway is a possible mechanism for CDDP resistance in human laryngeal squamous cell carcinoma, HEp-2 cells.
    Toyozumi Y; Arima N; Izumaru S; Kato S; Morimatsu M; Nakashima T
    Int J Oncol; 2004 Sep; 25(3):721-8. PubMed ID: 15289875
    [TBL] [Abstract][Full Text] [Related]  

  • 14. High effectiveness of platinum(IV) complex with adamantylamine in overcoming resistance to cisplatin and suppressing proliferation of ovarian cancer cells in vitro.
    Kozubík A; Horváth V; Svihálková-Sindlerová L; Soucek K; Hofmanová J; Sova P; Kroutil A; Zák F; Mistr A; Turánek J
    Biochem Pharmacol; 2005 Feb; 69(3):373-83. PubMed ID: 15652229
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A novel gene, CRR9, which was up-regulated in CDDP-resistant ovarian tumor cell line, was associated with apoptosis.
    Yamamoto K; Okamoto A; Isonishi S; Ochiai K; Ohtake Y
    Biochem Biophys Res Commun; 2001 Feb; 280(4):1148-54. PubMed ID: 11162647
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Liposomal cisplatin can overcome chemotherapy resistance of A2780 ovarian cancer cells by inducing the extrinsic apoptotic pathway.
    Stölting DP; Koch M; Wiese M; Royer HD; Bendas G
    Int J Clin Pharmacol Ther; 2014 Jan; 52(1):78-81. PubMed ID: 24290409
    [No Abstract]   [Full Text] [Related]  

  • 17. Chitosan coated polylactic acid nanoparticle-mediated combinatorial delivery of cisplatin and siRNA/Plasmid DNA chemosensitizes cisplatin-resistant human ovarian cancer cells.
    Babu A; Wang Q; Muralidharan R; Shanker M; Munshi A; Ramesh R
    Mol Pharm; 2014 Aug; 11(8):2720-33. PubMed ID: 24922589
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The role of topotecan for extending the platinum-free interval in recurrent ovarian cancer: an in vitro model.
    Horowitz NS; Hua J; Gibb RK; Mutch DG; Herzog TJ
    Gynecol Oncol; 2004 Jul; 94(1):67-73. PubMed ID: 15262121
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cisplatin inhibits paclitaxel-induced apoptosis in cisplatin-resistant ovarian cancer cell lines: possible explanation for failure of combination therapy.
    Judson PL; Watson JM; Gehrig PA; Fowler WC; Haskill JS
    Cancer Res; 1999 May; 59(10):2425-32. PubMed ID: 10344753
    [TBL] [Abstract][Full Text] [Related]  

  • 20. IGFBP-3 hypermethylation-derived deficiency mediates cisplatin resistance in non-small-cell lung cancer.
    Ibanez de Caceres I; Cortes-Sempere M; Moratilla C; Machado-Pinilla R; Rodriguez-Fanjul V; Manguán-García C; Cejas P; López-Ríos F; Paz-Ares L; de CastroCarpeño J; Nistal M; Belda-Iniesta C; Perona R
    Oncogene; 2010 Mar; 29(11):1681-90. PubMed ID: 20023704
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.